BASEL, SWITZERLAND--(Marketwire - April 15, 2008) - Basilea Pharmaceutica Ltd. (SWX: BSLN) announces that it has opened an additional phase III study to evaluate the efficacy and safety of isavuconazole in treating serious and life-threatening invasive fungal infections. Isavuconazole's breadth of spectrum in vitro and its favorable pharmacokinetic profile formed the basis of this open label study.
